8-K: Aclaris Therapeutics Reports Positive Phase 2a Results for ATI-2138 in Atopic Dermatitis

Aclaris Therapeutics announced positive top-line results from its Phase 2a clinical trial of ATI-2138 for moderate-to-severe atopic dermatitis, demonstrating a favorable tolerability profile and clinically meaningful efficacy.

Summary

• Aclaris Therapeutics reported positive top-line results from its open-label, single-arm Phase 2a trial of ATI-2138, an investigational oral covalent ITK/JAK3 inhibitor, in 14 patients with moderate-to-severe atopic dermatitis (AD).
• The trial achieved its primary endpoint, confirming a favorable tolerability profile for ATI-2138, with no severe adverse events (SAEs) or treatment-emergent adverse events (TEAEs) observed.
• Efficacy results showed a mean improvement in Eczema Area and Severity Score (EASI) of 60.5% (median 76.8%) at Week 12 for the per protocol population (n=10).
• Excluding a single statistical molecular outlier patient, the mean EASI improvement at Week 12 was 77.1% (median 82.1%) for the remaining 9 patients.
• At Week 12, 62.5% of patients (n=8) experienced a 4-point improvement in Peak Pruritus Numerical Rating Scale (PP-NRS), which is considered a clinically meaningful reduction in itch.
• Pharmacodynamic (PD) analyses confirmed modulation of both ITK and JAK3 pathways, with near complete and sustained ITK target occupancy (~90% at peak, 60-70% at trough) and high JAK3 inhibition (~80% at peak, ~20% at trough).
• PD data also showed significant reduction of multiple inflammatory pathways (Th1, Th2, Th17, TCR (ITK) pathways) and fibrosis-related markers, consistent across skin biopsies, tape strips, and patient plasma.
• ATI-2138 is a dual ITK/JAK3 inhibitor, demonstrating 44.4x greater potency for ITK and 5.4x greater potency for JAK3 compared to ritlecitinib in human whole blood assays, and 15-38x more potent than CPI-818 for ITK enzyme activity.
• The company intends to further develop ATI-2138 in alopecia areata and explore other indications, with preclinical work ongoing for next-generation ITK inhibitors expected to lead to new INDs starting in 2026.
• Aclaris expects its cash runway to extend into the second half of 2028.

Sentiment

Score: 9

Explanation: The filing reports highly positive top-line Phase 2a results for ATI-2138, demonstrating excellent safety and efficacy comparable to approved therapies. The strong pharmacodynamic data validates the unique mechanism, and the company outlines clear, ambitious next steps for the ITK franchise, including expansion into alopecia areata and development of next-generation compounds. The cash runway into H2 2028 also provides financial stability.

Positives

• ATI-2138 demonstrated a very favorable tolerability profile with no severe adverse events or discontinuations due to adverse events.
• Efficacy results for ATI-2138 in atopic dermatitis, including EASI score improvements (mean 77.1% excluding outlier) and itch reduction (62.5% achieving 4-point PP-NRS improvement), are comparable to approved JAK and IL-4/-13 inhibitors.
• Pharmacodynamic data strongly validate the therapeutic potential of ITK inhibition and confirm the dual mechanism of action of ATI-2138 on ITK and JAK3 pathways.
• The drug showed significant downregulation of key inflammatory markers (Th1, Th2, Th17, TCR pathways) and fibrosis-related markers, indicating broad anti-inflammatory activity.
• ATI-2138 exhibits superior potency for ITK and JAK3 inhibition compared to ritlecitinib and CPI-818, suggesting a best-in-class potential.
• The positive Phase 2a results provide strong conviction for further development of ATI-2138 in alopecia areata and other immuno-inflammatory diseases.
• The company has a clear pipeline strategy with ongoing preclinical work for next-generation ITK inhibitors and a robust clinical catalyst calendar through 2026.
• No evidence of global immune suppression was observed, with no significant perturbations in T cells/T cell subsets, B cells, or NK cells.

Risks

• Uncertainties are inherent in the conduct of clinical trials, which could impact future development and results.
• Reliance on third parties for aspects of development over which full control may not always be maintained.
• Ability to enter into strategic partnerships on commercially reasonable terms is not guaranteed.
• The macroeconomic environment presents uncertainties that could affect business operations and financial performance.
• No head-to-head clinical studies have been conducted against JAK or IL-4/13 inhibitors, requiring caution when comparing data across studies due to differences in trial designs and subject characteristics.
• Other risks and uncertainties are described in the Risk Factors section of the Annual Report on Form 10-K for the year ended December 31, 2024, and other SEC filings.

Future Outlook

Aclaris Therapeutics intends to further develop ATI-2138 in alopecia areata and is exploring other indications relevant to its mechanism of action. Preclinical work is ongoing for next-generation ITK inhibitors, with new Investigational New Drug (IND) submissions expected to begin in 2026. The company also anticipates several clinical milestones for other programs, including ATI-052 and Bosakitug (ATI-045), with top-line data expected in early 2026 and 2H 2026, respectively.

Management Comments

• Dr. Neal Walker, Chief Executive Officer of Aclaris, stated that the trial confirmed the strong tolerability profile of ATI-2138, tested the mechanism in AD before initiating work in other diseases like alopecia areata, and further validated ITK as an important therapeutic target, achieving each objective.
• Dr. Walker noted that the observed efficacy results, even at a low dose, suggest responses in line with, if not better than, approved therapies, and that PD results confirmed the potential of targeting ITK, including strong downregulation of key ITK-dependent markers and an interesting antifibrotic effect.
• Emma Guttman, M.D., Ph.D., Waldman Professor of Dermatology and Immunology at Mount Sinai, expressed excitement about the anti-inflammatory activity and therapeutic potential for ATI-2138 and ITK as a target, highlighting strong downregulation of inflammatory markers and the potential to address Th2 and Th1/Th17 mediated diseases.

Industry Context

The positive Phase 2a results for ATI-2138 position Aclaris Therapeutics as a potential innovator in the immuno-inflammatory disease space, particularly for atopic dermatitis and potentially alopecia areata. The drug's unique dual ITK/JAK3 inhibition mechanism offers a differentiated approach compared to existing JAK and IL-4/13 inhibitors, potentially providing comparable efficacy with an improved tolerability profile, addressing a key concern with some current treatments. This could allow Aclaris to capture market share in a competitive landscape dominated by therapies like Dupixent (IL-4/13 inhibitor) and various JAK inhibitors.

Comparison to Industry Standards

• ATI-2138's efficacy results, with a mean EASI improvement of 77.1% (excluding outlier) at Week 12, are stated to be comparable to those seen with approved JAK and IL-4 and -13 inhibitor products in moderate-to-severe AD.
• The 62.5% of patients achieving a 4-point improvement in PP-NRS at Week 12 is also noted as comparable to results from published Phase 2 and Phase 3 studies of approved JAK and IL-4 and -13 inhibitor products.
• ATI-2138 is highlighted as being 44.4x more potent than ritlecitinib (a JAK3 inhibitor) for inhibiting anti-CD3 induced IFN production (ITK activity) and 5.4x more potent for inhibiting JAK3 dependent IL-2 induced IFN production in human whole blood.
• ATI-2138 is also significantly more potent than CPI-818 (Soquelitinib), being 15-38x more potent in inhibiting ITK enzyme activity and approximately 100x more potent in blocking Th2 derived cytokines (IL4, IL-5, IL-13).
• The favorable tolerability profile of ATI-2138, without certain risks associated with other agents in the class, suggests a potential advantage over some approved JAK inhibitors that carry significant safety warnings.

Stakeholder Impact

• Shareholders: Positive clinical trial results are likely to increase investor confidence and potentially lead to an increase in share price due to de-risking of the pipeline asset and validation of the ITK franchise.
• Patients with Atopic Dermatitis: The positive safety and efficacy profile of ATI-2138 suggests a promising new treatment option, potentially offering improved tolerability compared to existing therapies.
• Patients with Alopecia Areata: The company's intent to develop ATI-2138 for alopecia areata offers hope for a new therapeutic approach for this condition.
• Employees: Positive trial results and a robust pipeline could lead to increased job security and potential growth opportunities within the company.
• Regulatory Authorities: The successful Phase 2a results will inform future regulatory submissions and discussions for ATI-2138 and other ITK inhibitors.

Next Steps

• Further develop ATI-2138 in alopecia areata.
• Explore other indications relevant to the mechanism of action of ATI-2138.
• Continue preclinical work for next-generation ITK inhibitors, with new IND submissions expected to start in 2026.
• ATI-052 IND Clearance by FDA (2025).
• Bosakitug (ATI-045) Initiation of Phase 2 Trial in Atopic Dermatitis (2025).
• ATI-052 Initiation of Phase 1a/1b Program (2025).
• ATI-052 Completion of dosing in Phase 1a SAD/MAD HV Portion (Year-end 2025).
• ATI-052 Phase 1a/1b Top Line Data (Phase 1a SAD/MAD: Early 2026; Phase 1b POC: 2H 2026).
• Bosakitug (ATI-045) Atopic Dermatitis Phase 2 Top Line Data (2H 2026).
• ATI-2138 Initiation of Phase 2 in Second Indication (2026).
• ITK Selective Program IND Submission and Start of Phase 1 Program (2026).

Key Dates

Recommendation

The positive top-line Phase 2a results for ATI-2138 in atopic dermatitis are highly encouraging, demonstrating a strong safety profile and efficacy comparable to approved therapies, with a potentially improved tolerability. This significantly de-risks the asset and validates Aclaris's ITK franchise. The company's clear strategic plan to advance ATI-2138 into alopecia areata and develop next-generation ITK inhibitors provides a robust pipeline for future growth. The stated cash runway into the second half of 2028 also provides financial stability. Given these factors, the stock presents a compelling investment opportunity.

Keywords

Aclaris Therapeutics, ATI-2138, Atopic Dermatitis, Eczema, ITK Inhibitor, JAK3 Inhibitor, Clinical Trial, Phase 2a, Immunology, Inflammation, Dermatology, Alopecia Areata, Biopharmaceutical, Drug Development, Clinical Results, Pharmacodynamics, EASI, PP-NRS